Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 80Dermatologic 4Sarcoma 1Other hematologic neoplasm 1

Conditions

Dendritic Cell Sarcoma, Interdigitating 3Sarcoma, Kaposi 1Lymphomatoid Papulosis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma, B-Cell 1Hodgkin Disease 1

Interventions

Cyclophosphamide 42fludarabine phosphate 33Peripheral Blood Stem Cell Transplantation 32Mycophenolic Acid 26Whole-Body Irradiation 23Cyclosporine 23Busulfan 23Radiotherapy 19Filgrastim 19Antilymphocyte Serum 19Tacrolimus 16Melphalan 16Methotrexate 12Methylprednisolone 10Cord Blood Stem Cell Transplantation 10Etoposide 8Thiotepa 6sargramostim 5fludarabine 5Therapeutics 5aldesleukin 4Sirolimus 4Cytarabine 4Polymerase Chain Reaction 3Paclitaxel 3Granulocyte Colony-Stimulating Factor 3Carmustine 3Amplified Fragment Length Polymorphism Analysis 3Alemtuzumab 3thymoglobulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × Brentuximab Vedotin × Sarcoma × Clear all
NCT00051597 2011-10-12

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Seagen Inc.

Phase 1/2 Completed
70 enrolled
DermatologicLymphoidSarcoma

Hodgkin Disease, Sarcoma, Kaposi, Lymphoma, B-Cell, Lymphoma, T-Cell, Cutaneous, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡